Le Lézard
Classified in: Health
Subjects: SCZ, SBS

BIPRI is Optimizing Nutrition to Help Improve Adults' Memory


FRANKLIN, Tenn., Oct. 17, 2019 /PRNewswire/ -- Four in ten adults in the U.S. age 65 or older have some form of age-associated memory loss, according to findings published in The British Medical Journal. "About 10% of people aged 65 years or older have mild cognitive impairment, and nearly 15% of them develop Alzheimer's disease each year," the study continues.

Pharmacists and brain science experts at BIPRI Wellness are helping adults of all ages and health backgrounds optimize their nutrition in order to promote improved brain health and support for cognitive function.

Real Life Improvements: Memory & Cognitive Function

One of the company's latest pharmacist-formulated nootropics, Brain & Memory Fuel, is already making an impact among users looking to improve their memory and ability to focus. According to one customer, "Just like most people, when I turned 50, I felt my memory was not nearly as good as it used to be. My ability to quickly recall facts and figures was noticeably slowing down and it worried me. I started taking the supplement from BIPRI, and now I feel my memory has not been this good in 30 years."

Research Behind Brain & Memory Fuel

A blend of nutrients and botanical extracts, Brain & Memory Fuel contains powerful nootropics, such as acetyl-l-carnitine, bacopa, Sharp-PS (phosphatidylserine) and huperzine A.

According to a 2016 study, "Bacopa monnieri has also been shown to improve specific domains of cognition, sensitive to age associated cognitive decline (particularly processing speed and memory)."

A 2014 study reports, "Improvement of some memory functions has been observed in cognitively impaired subjects as a result of PS supplementation [...]"

"HupA treatment significantly attenuated markers of neuroinflammation and oxidative stress in the injured mice. Taken together, HupA was effective in reducing neuroinflammation, oxidative stress and behavioral recovery after TBI," reports a 2017 study.

"We're very excited about the potential for Brain & Memory Fuel among adults looking to optimize their memory, focus, and cognitive performance," says BIPRI founder, Mickey Mitchell. "The feedback from customers has been encouraging, spurring us on to continue in our mission of creating tools for a healthier brain."

ABOUT BIPRI

BIPRI was founded by Mickey Mitchell with an audacious goal: find a better way to help promote brain wellness and provide hope for those suffering from brain-related issues. Our programs represent seven years of intense work with doctors, therapists, dietitians, chiropractors, and other medical professionals.

If you would like more information about this topic, please call Bob Hutchins at 888-549-5519, or email [email protected].

SOURCE BIPRI, LLC


These press releases may also interest you

at 05:45
The "Distribution Deals in Diagnostics 2016 to 2024" report has been added to  ResearchAndMarkets.com's offering. Distribution Deals in Diagnostics provides a detailed understanding and analysis of how and why companies enter distribution...

at 05:10
Neurology Devices: Global Markets is basically a detailed study or report about the worldwide market for medical tools used in treating neurological conditions. These devices could be anything from equipment that helps stimulate the nervous system to...

at 05:04
Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited...

at 04:28
GymNation, the homegrown UAE fitness brand, has today announced that due to unprecedented growth, it is reaching capacity across its 12 UAE gym locations and diversifying into a new market, brewing up a storm with the launch of its first-ever branded...

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...



News published on and distributed by: